The “wonderful” psychedelic drug of the 60’s can improve Parkinson’s symptoms for weeks: study

Here are some Groovy news.

An explosion of flexion of the mind of the past, which was a “wonderful drug” that could heal everything, from anxiety to addiction, is a comeback.

Psilocybin, the psychedelic compound that gave the “magical mushrooms” its Trippy reputation in the 1960’s, now shows a serious promise to improve their mood and motor function in people with Parkinson’s disease, according to a recent innovative study.

In the first trial of this type, researchers administered a single dose of psilocibine to patients fighting Parkinson’s, a degenerative brain disorder affecting about one million Americans.

The results? Not only a safe journey, but one that handed over weeks of relief from the tremors, the rigidity and the depression often plagued by patients.

“Many people do not realize this, but the symptoms of the mood in Parkinson are related to faster physical decline,” said Ellen Bradley, an assistant professor of Sciences in Psychiatry and Behavior at UC San Francisco, in a statement.

“And they are actually a stronger predictor of the quality of life of patients with Parkinson’s than their motor symptoms.”

The study, published in Neuropsychopharmacology, indicates that participants managed halucinogen well – there were no serious side effects or worsening symptoms – and also experienced significant increases in the mood, memory and movement that were hooked much after they stopped taking the drug.

It is also a historic first: so far no psychedelic has been tested in patients with a degenerative brain disease.

“We are still in very early stages of this work, but this first studio went far beyond what we expected,” Bradley said.

There is currently no care for Parkinson’s, although drugs like Levodopa can help patients manage their symptoms. The good news is that the treatment options are expanding.

Tavapadon, a new drug that mimics dopamine by directing certain receptors, has shown promise in clinical trials by reducing motor fluctuations and maintaining control of symptoms with less side effects than traditional therapies.

Produce – a continuous infusion therapy for the first time in the United Kingdom – was approved by the United States Food and Drug Administration last fall.

Innovative approaches to the psychological aspects of the disease have also been successful: Tandem cycling is particularly popular.

Some neoyorcan people even find relief playing Pingpong.

“I just can’t get it enough,” said NYU teacher Bill Easterly, he said to The Post earlier. “When I play Pingpong, I only feel that my brain comes to life.”

In the meantime, the UCSF (TRPR) translational psychedelic research program plans to be larger trials to further investigate the potential of the psilocibine.

If future studies confirm these findings, magical mushrooms could become a powerful new tool in the fight against Parkinson’s.

“The vast majority of brain diseases still have no interventions that change the course of the disease,” said Senior Study Author and TRPR director Joshua Woolley.

“We can often treat symptoms, but we do not alter the trajectory or avoid the decrease. Now, this begins to change. These results increase the exciting possibility that the psilocibine can help the brain repair.”